{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-067452","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.584644+00:00","generated_at":"2026-05-22T01:21:54.944375+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gyre Therapeutics Q1 net income $3.7M, revenue $22.1M; reaffirms FY2025 guidance $118–128M","bullets":["Net income $3.7M ($0.03 basic EPS) vs $9.9M in Q1 2024; revenue $22.1M, down 19% due to ETUARY decline from prior year one-time campaign.","FY2025 revenue guidance reiterated at $118–128M (2024: $105.8M); commercial launches of nintedanib (May 2025) and avatrombopag (March 2025) expected to drive H2 growth.","Phase 3 Hydronidone trial for CHB liver fibrosis completed data lock; topline results expected Q2 2025. IND approved for pirfenidone for radiation-induced lung injury.","Non-GAAP adjusted net income $2.9M vs $8.2M; cash $51.3M as of March 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-067452","json":"https://secwatch.observer/filing/0000950170-25-067452.json","markdown":"https://secwatch.observer/filing/0000950170-25-067452.md","text":"https://secwatch.observer/filing/0000950170-25-067452.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000095017025067452/0000950170-25-067452-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000095017025067452/gyre-20250509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:21:54.944375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}